NASDAQ:KIDS - OrthoPediatrics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $72.50
  • Forecasted Upside: 9.43 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$66.25
▼ -1.8 (-2.65%)

This chart shows the closing price for KIDS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OrthoPediatrics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KIDS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KIDS

Analyst Price Target is $72.50
▲ +9.43% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for OrthoPediatrics in the last 3 months. The average price target is $72.50, with a high forecast of $80.00 and a low forecast of $57.00. The average price target represents a 9.43% upside from the last price of $66.25.

This chart shows the closing price for KIDS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in OrthoPediatrics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/6/2021JMP SecuritiesBoost Price TargetOutperform$70.00 ➝ $77.00Low
8/5/2021Piper SandlerBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $80.00Low
6/14/2021Needham & Company LLCBoost Price TargetBuy$70.00 ➝ $77.00Medium
5/7/2021Truist SecuritiesBoost Price Target$64.00 ➝ $72.00Low
5/7/2021TruistBoost Price Target$64.00 ➝ $72.00Low
5/7/2021JMP SecuritiesBoost Price TargetOutperform$55.00 ➝ $70.00High
5/6/2021Piper SandlerReiterated RatingOverweight$62.00 ➝ $70.00High
4/19/2021Truist SecuritiesBoost Price Target$54.00 ➝ $64.00Low
4/19/2021TruistBoost Price Target$54.00 ➝ $64.00Low
4/6/2021Piper SandlerBoost Price Target$55.00 ➝ $62.00Low
10/7/2020BTIG ResearchBoost Price TargetBuy$54.00 ➝ $57.00High
8/5/2020Needham & Company LLCBoost Price TargetBuy$49.00 ➝ $57.00High
6/16/2020Stifel NicolausBoost Price Target$48.00 ➝ $55.00Low
6/8/2020BTIG ResearchBoost Price TargetBuy$48.00 ➝ $54.00High
5/14/2020JMP SecuritiesLower Price TargetMarket Outperform$50.00 ➝ $48.00Medium
5/6/2020BTIG ResearchReiterated RatingBuy$48.00Medium
5/6/2020Needham & Company LLCBoost Price TargetBuy$46.00 ➝ $49.00Low
4/3/2020BTIG ResearchLower Price TargetBuy$50.00 ➝ $48.00Medium
4/2/2020Needham & Company LLCLower Price TargetBuy$56.00 ➝ $46.00Low
3/8/2020BTIG ResearchReiterated RatingBuy$50.00Medium
3/6/2020Stifel NicolausBoost Price TargetBuy$44.00 ➝ $50.00Low
1/7/2020SunTrust BanksInitiated CoverageBuy$54.00Low
12/16/2019Piper Jaffray CompaniesBoost Price TargetOverweight$44.00 ➝ $50.00Low
11/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$40.00 ➝ $44.00Low
6/19/2019Needham & Company LLCInitiated CoverageBuy ➝ Buy$53.00Low
5/10/2019BTIG ResearchReiterated RatingBuy$44.00Medium
4/29/2019BTIG ResearchReiterated RatingBuy$44.00Medium
3/8/2019BTIG ResearchBoost Price TargetBuy$44.00Low
2/20/2019JMP SecuritiesInitiated CoverageMkt Outperform ➝ Outperform$44.00Medium
1/2/2019BTIG ResearchBoost Price TargetTop Pick ➝ Buy$37.00Low
7/5/2018Piper Jaffray CompaniesBoost Price TargetOverweight$24.00 ➝ $30.00High
6/27/2018William BlairReiterated RatingOutperformHigh
1/5/2018BTIG ResearchReiterated RatingBuy$24.00Medium
11/6/2017William BlairInitiated CoverageOutperform ➝ OutperformN/A
11/6/2017Stifel NicolausInitiated CoverageBuy ➝ Buy$23.00N/A
11/6/2017BTIG ResearchInitiated CoverageBuy ➝ Buy$24.00N/A
11/6/2017Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$24.00N/A
(Data available from 9/27/2016 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/1/2021
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/31/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/30/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/29/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2021
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/28/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
9/27/2021

Current Sentiment

  • 2 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
OrthoPediatrics logo
OrthoPediatrics Corp. is a medical device company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. Its products includes PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, RESPONSE Spine, Bandloc and Pediguard. The company was founded by Erin Springer Yount and Nick A. Deeter in August 2006 and is headquartered in Warsaw, IN.
Read More

Today's Range

Now: $66.25
Low: $66.00
High: $68.33

50 Day Range

MA: $66.04
Low: $59.83
High: $71.52

52 Week Range

Now: $66.25
Low: $38.01
High: $72.50

Volume

73,690 shs

Average Volume

139,490 shs

Market Capitalization

$1.30 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of OrthoPediatrics?

The following Wall Street research analysts have issued stock ratings on OrthoPediatrics in the last year: BTIG Research, JMP Securities, Needham & Company LLC, Piper Sandler, TheStreet, Truist, Truist Securities, and Zacks Investment Research.
View the latest analyst ratings for KIDS.

What is the current price target for OrthoPediatrics?

6 Wall Street analysts have set twelve-month price targets for OrthoPediatrics in the last year. Their average twelve-month price target is $72.50, suggesting a possible upside of 9.4%. Piper Sandler has the highest price target set, predicting KIDS will reach $80.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $57.00 for OrthoPediatrics in the next year.
View the latest price targets for KIDS.

What is the current consensus analyst rating for OrthoPediatrics?

OrthoPediatrics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe KIDS will outperform the market and that investors should add to their positions of OrthoPediatrics.
View the latest ratings for KIDS.

What other companies compete with OrthoPediatrics?

How do I contact OrthoPediatrics' investor relations team?

OrthoPediatrics' physical mailing address is 2850 Frontier Drive, Warsaw IN, 46582. The company's listed phone number is (574) 268-6379 and its investor relations email address is [email protected] The official website for OrthoPediatrics is www.orthopediatrics.com.